Overview of Advances in Recent Years for Patients With AML
Daniel A. Pollyea, MD, MS, discusses how far the field of acute myeloid leukemia has come in the last 1 to 2 years.
Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses how far the field of acute myeloid leukemia (AML) has come in the last 1 to 2 years.
For years, this patient population had limited treatment options with poor outcomes, according to Pollyea. Over the last few years, there has been a huge acceleration in terms of options available for these patients.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
